StockData
Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc. (RCKT) stock

RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$2.11−0.05 (-2.31%)

Close on Nov 17, 2026Market cap $231.62MP/E –Yield –

Rocket Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Rocket Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$184.04M. For fiscal 2025 it was -$222.85M. The highest annual figure on record is -$70.83M in fiscal 2018.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$222.85M–
FY2024Dec 31, 2024-$266.01M–
FY2023Dec 31, 2023-$254.76M–
FY2022Dec 31, 2022-$220.44M–
FY2021Dec 31, 2021-$164.05M–
FY2020Dec 31, 2020-$133.16M–
FY2019Dec 31, 2019-$75.73M–
FY2018Dec 31, 2018-$70.83M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$45.32M–
Q1 FY2026Mar 31, 2026-$46.91M–
Q4 FY2025Dec 31, 2025-$42.26M–
Q3 FY2025Sep 30, 2025-$49.55M–
Q2 FY2025Jun 30, 2025-$69.15M–
Q1 FY2025Mar 31, 2025-$61.89M–
Q4 FY2024Dec 31, 2024-$60.89M–
Q3 FY2024Sep 30, 2024-$67.52M–
Q2 FY2024Jun 30, 2024-$71.91M–
Q1 FY2024Mar 31, 2024-$65.68M–
Q4 FY2023Dec 31, 2023-$61.88M–
Q3 FY2023Sep 30, 2023-$64.23M–
Q2 FY2023Jun 30, 2023-$67.56M–
Q1 FY2023Mar 31, 2023-$61.09M–
Q4 FY2021Dec 31, 2021-$43.32M–
Q3 FY2021Sep 30, 2021-$48.85M–
Q2 FY2021Jun 30, 2021-$33.35M–
Q1 FY2021Mar 31, 2021-$38.55M–
Q4 FY2020Dec 31, 2020-$58.61M–
Q3 FY2020Sep 30, 2020-$27.09M–
Q2 FY2020Jun 30, 2020-$23.46M–
Q1 FY2020Mar 31, 2020-$24.00M–
Q4 FY2019Dec 31, 2019-$19.55M–
Q3 FY2019Sep 30, 2019-$19.07M–

More Rocket Pharmaceuticals figures

See a number that looks wrong?